The Middle EAST Spindle Cell Sarcoma Treatment Market was valued at USD 0.45 billion in 2024 and is projected to reach USD 1.20 billion by 2034, registering a CAGR of 10.00%. This growth trajectory is underpinned by several factors, including the rising incidence of spindle cell sarcoma, advancements in treatment modalities, and increasing healthcare expenditure across the region. The demand...